CYT Cyteir Therapeutics Inc

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2024

 

 

Cyteir Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-40499	45-5429901
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
P.O. Box 80084
Stoneham, Massachusetts				02180
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 285-4140

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		CYT		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

---

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

 

On March 7, 2024, Cyteir Therapeutics, Inc. (the “Company”) delivered formal notice to The Nasdaq Stock Market that the Company intends to voluntarily delist its common stock, par value $0.001 per share (the “Common Stock”), from the Nasdaq Global Select Market (“Nasdaq”) in connection with the Company’s voluntary Plan of Complete Liquidation and Dissolution previously approved by the Company’s Board of Directors and stockholders.

 

The Company expects to file a Notification of Removal from Listing and/or Registration on Form 25 with the Securities and Exchange Commission (the “SEC”) on or about March 18, 2024 to effect the voluntary delisting of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the delisting will be effective on or about March 28, 2024, ten days after the filing of the Form 25. In connection with the foregoing, the Company requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on March 18, 2024. Following the effectiveness of the delisting, the Company intends to file a Form 15 with the SEC to terminate the registration of the Common Stock under Section 12(g) of the Exchange Act, thereby suspending the Company’s Exchange Act reporting obligations.

 

A copy of the press release announcing the matters summarized above is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 8.01 Other Events

 

On March 7, 2024, the Company issued a press release regarding the matters disclosed in Item 3.01 above. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.		Description
99.1		Press Release of Cyteir Therapeutics, Inc. dated March 7, 2024
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			CYTEIR THERAPEUTICS, INC.
Date:	March 7, 2024	By:	/s/ David Gaiero
			Name: David Gaiero Title: Chief Financial Officer and Treasurer

 

---

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

LEXINGTON, MA— March 7, 2024 — Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced that it has formally notified The Nasdaq Stock Market (“Nasdaq”) of its intent to delist the Company’s common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to file a certificate of dissolution with the Delaware Secretary of State on or about March 20, 2024 and close its stock transfer books at the close of business on this date. The official delisting of Cyteir’s common stock will be effective on or about March 28, 2024, ten days after the filing of the Form 25.

Cyteir also intends to file a Form 15 with the SEC as soon as practicable following the effectiveness of the delisting to indefinitely suspend its reporting obligations under the Securities Exchange Act of 1934, as amended.

The voluntary delisting and deregistration are part of Cyteir’s Plan of Complete Liquidation and Dissolution previously approved by Cyteir’s board of directors and by Cyteir’s stockholders at a special meeting held on November 16, 2023. Cyteir’s board of directors considered a number of factors in determining to delist and deregister its common stock, including the costs and expenses associated with being a publicly traded company, the auditing, legal and other costs associated with continuing to make SEC filings, and the burdens placed on Cyteir’s management to comply with the continued listing and reporting requirements, all in light of Cyteir’s planned dissolution and liquidation.

Forward-Looking Statements

This press release contains “forward-looking statements,” including with respect to the timing of Cyteir’s planned dissolution and liquidation. The words ”believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “could,” “target,” “predict,” “seek” and similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, which could cause actual results to differ materially from those contained in or implied by the forward-looking statements, including the risks and uncertainties identified under the heading “Risk Factors” in Cyteir’s definitive proxy statement filed with the Securities and Exchange Commission on October 12, 2023.

The forward-looking statements contained in this press release are based on management's current views, plans, estimates, assumptions, and projections with respect to future events, and, except to the extent required by law, Cyteir does not undertake and specifically disclaims any obligation to update any forward-looking statements.

---

v3.24.0.1

Document and Entity Information	Mar. 07, 2024
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001662244
Document Type	8-K
Document Period End Date	Mar. 07, 2024
Entity Registrant Name	Cyteir Therapeutics, Inc.
Entity Incorporation State Country Code	DE
Securities Act File Number	001-40499
Entity Tax Identification Number	45-5429901
Entity Address, Address Line One	P.O. Box 80084
Entity Address, City or Town	Stoneham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02180
City Area Code	857
Local Phone Number	285-4140
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.001 par value per share
Trading Symbol	CYT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

---